Flexeril Additional Efficacy Data Requested By FDA Advisory Committee
This article was originally published in The Tan Sheet
Executive Summary
Merck should conduct more studies examining the efficacy of Flexeril 5 mg (cyclobenzaprine) in support of an Rx-to-OTC switch for the muscle relaxant, members of FDA's Nonprescription Drugs and Arthritis Advisory Committees maintained during a review of the drug in Gaithersburg, Md. July 20.